KOURAGE Trial Update: CalciMedica is currently enrolling patients in the Phase 2 KOURAGE trial for Auxora™ targeting acute kidney injury (AKI) with respiratory failure, with data expected in the first half of 2026.
FDA Discussions on Acute Pancreatitis: The company has had positive discussions with the FDA regarding the design of a pivotal trial for acute pancreatitis, which is anticipated to be finalized in the first half of 2026.
Financial Position: As of September 30, 2025, CalciMedica reported a cash position of $14.1 million, expected to fund operations into the second half of 2026, despite a net loss of $7.8 million for the third quarter.
Collaboration with Telperian: CalciMedica announced a collaboration with Telperian to utilize AI-driven analytics for optimizing the design of its pivotal trial in acute pancreatitis, leveraging insights from previous Auxora trials.
Wall Street analysts forecast CALC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CALC is 20.00 USD with a low forecast of 20.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast CALC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CALC is 20.00 USD with a low forecast of 20.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.120
Low
20.00
Averages
20.00
High
20.00
Current: 5.120
Low
20.00
Averages
20.00
High
20.00
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$16
2025-04-01
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$16
AI Analysis
2025-04-01
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$16
2025-03-04
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$16
2025-03-04
Reiterates
Strong Buy
Reason
About CALC
CalciMedica, Inc. is a clinical-stage biopharmaceutical company. The Company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for inflammatory and immunologic diseases. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase IIb trial (called CARPO) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase I/II asparaginase-induced pancreatic toxicity (AIPT) study (called CRSPA).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
